Full Breakdown
Efficacy of Medicinal Cannabis for Mental Health Conditions Under Scrutiny
3/17/2026, 9:43:46 PM
Major Findings from the Lancet Psychiatry Review
A recent paper published in *Lancet Psychiatry* represents the largest review to date on the safety and efficacy of cannabinoids for mental health conditions. The study concluded that there is no evidence supporting the effectiveness of medicinal cannabis in treating anxiety, depression, or post-traumatic stress disorder (PTSD). This review emerges amid a significant increase in the prescription of cannabinoid medications in Australia, which has seen over one million approvals and a tripling of sales in the past four years.
Regulatory Context and Concerns
The Australian Medical Association (AMA) has expressed concerns regarding the prescribing practices of medicinal cannabis. AMA President Dr. McMullen emphasized the need for robust regulatory oversight, stating that while medicinal cannabis may benefit certain conditions like epilepsy and chemotherapy-induced nausea, its use for mental health disorders is not supported by sufficient evidence. He noted, “Medicinal cannabis should not displace proven, effective treatments, particularly in mental healthcare where evidence-based therapies already exist.”
The Therapeutic Goods Administration (TGA) is currently reviewing the regulations surrounding medicinal cannabis, prompted by the surge in prescriptions for unapproved products. Anxiety is reported as one of the most common reasons for prescribing high-potency tetrahydrocannabinol (THC) products in Australia.
Perspectives from Medical Professionals
Associate Professor Vicki Kotsirilos, a Melbourne GP and early adopter of medicinal cannabis prescriptions, described the findings of the review as significant. She stated that the comprehensive nature of the study should guide health practitioners in their prescribing decisions. Kotsirilos noted that while there is evidence for the efficacy of medicinal cannabis in specific conditions, such as reducing seizures in epilepsy and managing pain, the evidence for mental health disorders remains inadequate.
Criticism of Current Practices
The review has prompted calls for improved studies on medicinal cannabis, advocating for larger and more representative participant samples. Critics argue that the current prescribing practices may lead to serious adverse outcomes, as medicinal cannabis is often used for conditions where it is contraindicated or should be closely monitored. Dr. McMullen highlighted the importance of integrating evidence-based non-pharmacological treatments, such as cognitive behavior therapy and mindfulness, into patient care.
Conclusion
The findings from the *Lancet Psychiatry* review raise critical questions about the role of medicinal cannabis in treating mental health disorders. As regulatory bodies like the TGA reassess the landscape of cannabinoid prescriptions, the medical community is urged to prioritize evidence-based practices to ensure patient safety and effective treatment outcomes.
Verbatim Quotes
- “Medicinal cannabis should not displace proven, effective treatments, particularly in mental healthcare where evidence based therapies already exist.” — Dr. McMullen, AMA President
- “‘This is the most comprehensive study to date found in the literature and should help set up clinical guidance for health practitioners when choosing to prescribe medicinal cannabis,’ she told newsGP.” — Associate Professor Vicki Kotsirilos, GP
